Foresight Diagnostics and Roche Enter Licensing Agreement for PhasED-Seq™ Technology in Non-Hodgkin's Lymphoma - Candlesense

Foresight Diagnostics and Roche Enter Licensing Agreement for PhasED-Seq™ Technology in Non-Hodgkin's Lymphoma

(RHHBY) The Agreement Closes the Litigation Between the Parties BOULDER, Colo., Aug. 29, 2025 /PRNewswire/ -- Foresight Diagnostics ("Foresight") today announced that it has entered into a limited licensing agreement with Roche Molecular Systems and Roche Sequencing Systems (together, "Roche")...